CD274 and neoplasm: In the USA, the anti-PD-L1 antibody atezolizumab is approved for the treatment of patients with locally advanced or metastatic UBC, ineligible for cisplatin-containing therapy, whose tumors have PD-L1-stained IC, covering ≥ 5% of the tumor area, or ineligible for any platinum-containing therapy regardless of PD-L1 expression [13].